Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05448677 Terminated - Clinical trials for Hepatocellular Carcinoma

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

ABE-LIVER
Start date: December 15, 2022
Phase: Phase 2
Study type: Interventional

The study will assess the efficacy of Ezurpimtrostat in association with standard of care (Atezolizumab-Bevacizumab), compared to standard of care alone, as first line treatment in patients with unresectable hepatocellular carcinoma.The study drug which is tested is the Ezurpimtrostat in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.

NCT ID: NCT05249569 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Start date: November 4, 2022
Phase: Phase 2
Study type: Interventional

Across cancer types, immune checkpoint inhibitors have been shown to induce complete response, partial response, and stable disease after initial evidence of radiographic increase in tumor burden. Treatment beyond progression should be considered when the patient is stable (or improving) symptomatically and if tumor reassessment can be performed within a short period.

NCT ID: NCT05184283 Terminated - Clinical trials for Hepatocellular Carcinoma

Utilization of MAsS in Patients Undergoing LT for HCC

Start date: June 16, 2022
Phase:
Study type: Observational

The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.

NCT ID: NCT05093608 Terminated - Clinical trials for Hepatocellular Carcinoma

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Start date: November 3, 2021
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.

NCT ID: NCT04653389 Terminated - Clinical trials for Hepatocellular Carcinoma

Perioperative Therapy for Hepatocellular Carcinoma

Start date: December 26, 2020
Phase: Phase 2
Study type: Interventional

This study aims to observe and evaluate the efficacy and safety of the perioperative multidisciplinary therapy that combines the preoperative transarterial chemoembolization(TACE) and the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection with or without radiotherapy of vein tumor thrombus followed by postoperative anti-PD-1 injection in the treatment of technically resectable hepatocellular carcinoma patients with vein thrombosis.

NCT ID: NCT04649671 Terminated - Clinical trials for Hepatocellular Carcinoma

The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin Resistance

Start date: March 2, 2021
Phase: N/A
Study type: Interventional

Exercise is predicted to have positive effect among patients with hepatocellular carcinoma (HCC). However, little attention has been paid to the role of physical activity with wearable device in the management of HCC patients in the aspect of improvement in insulin resistance. We designed this study to investigate whether personalized exercise with mobile health program improves insulin resistance without decompensation in HCC patients with insulin resistance.

NCT ID: NCT04635527 Terminated - Clinical trials for Hepatocellular Carcinoma

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

Start date: December 24, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.

NCT ID: NCT04629339 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of INCB086550 in Select Solid Tumors

Start date: September 2, 2021
Phase: Phase 2
Study type: Interventional

An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors

NCT ID: NCT04541173 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, randomized phase II study comparing the Y90 TARE followed by bevacizumab and atezolizumab treatment to the Y90 TARE treatment alone in unresectable advanced stage HCC.

NCT ID: NCT04502082 Terminated - Clinical trials for Hepatocellular Carcinoma

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Start date: April 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Open-label, dose escalation, multi-center, Phase I / II study to assess the safety of an autologous T-cell product (ET140203) in adult subjects with Alpha-fetoprotein (AFP)-positive/Human Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).